Intravenous administration of histamine causes an increase in choroidal blood flow and retinal vessel diameter in healthy subjects. The mechanism underlying this effect remains to be elucidated. In the present study we hypothesized that H 2 receptor blockade alters the hemodynamic effects of histamine in the choroid and the retina. 
Introduction
The importance of histamine as a regulator of vascular tone has been demonstrated for several vascular beds (6, 12) . Based on these experiments, it has been hypothesized that histamine may also play a role in the regulation of ocular blood flow. This hypothesis is supported by several in vitro experiments indicating a vasodilatory role of histamine in the ocular circulation (7) . Data of human experiments on the effect of histamine on ocular blood flow is, however sparse.
We could recently demonstrate that intravenous administration of histamine causes an increased mean flow velocity (MFV) in the ophthalmic artery (18) . This increase is paralleled by a vasodilatation of retinal vessels and an increase in choroidal blood flow (24) . However, the mechanism underlying this effect is unclear, because different subtypes of histamine receptors exist and the receptor responsible for the ocular vasodilator effects of histamine in vivo has yet to be identified (3, 4, 8) . Recent experiments in other vascular beds have identified both H 1 and H 2 receptors as possible candidates for vascular effects, but the H 2 type seems to be the dominant receptor participating in the vasodilator responses of histamine in many vascular beds (21) . Thus, the current study aimed to test the hypothesis that administration of cimetidine, a histamine type-2 receptor antagonist, is able to modify the blood flow response of intravenous histamine in the choroid and retina.
Effect of histamine and cimetidine on ocular blood flow
4/20
Material and Methods Subjects 18 healthy male non-smoking volunteers were included (age range: 21-35 years, mean: 25.5 years, SD: 3.0 years). The nature of the study was explained and all subjects signed a written informed consent to participate. The study protocol was approved by the Ethics Committee of Vienna University School of Medicine and followed the guidelines of GCP and the Declaration of Helsinki. Each subject passed a screening examination including medical history and physical examination, 12-lead electrocardiogram, complete blood count, activated partial thromboplastin time, thrombin time, fibrinogen, clinical chemistry (sodium, potassium, creatinine, uric acid, glucose, cholesterol, triglycerides, alanine amino-transferase, aspartate transcarbamylase,-glutamyl-transferase, alkaline phosphatase, total bilirubin, total protein), total IgE-antibodies, hepatitis A, B, C and HIV-serology, urine analysis, and a urine drug-screening. Only subjects with IgE plasma levels of less than 100kU/l were included. Subjects were excluded if any abnormality was found as part of the pretreatment screening unless the investigators considered the abnormality to be clinically irrelevant. Further exclusion criteria were history of migraine or other types of headaches. Moreover, an ophthalmic examination, including slit lamp biomicroscopy and indirect funduscopy, was performed. Inclusion criteria were normal ophthalmic findings, ametropia of less than 3 diopters and anisometropia of less than 1 diopter.
Study design
The dose of cimetidine was selected based on the results of a pilot study (n = 4; mean age: 26.1 years; age range: 22-31 years). In this open dose escalation study increasing doses of cimetidine of 0.3mg/min, 1mg/min, 1.6mg/min, 2.3mg/min were administered for 15 minutes each step. Systemic hemodynamic measurements and Effect of histamine and cimetidine on ocular blood flow
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blood flow measurements were performed using the same techniques as outlined for the main study at the end of each infusion step.
In the main experiment, subjects were studied in a randomized, double masked, two way crossover design with histamine in combination with the H 2 receptor antagonist cimetidine or placebo. Two study days were scheduled for each subject with washout periods of at least five days between study days. On both study days histamine was administered intravenously in a dose of 0.32µg/kg/min with a co-administration of either cimetidine in a dose of 2.3mg/min or placebo.
On the trial days subjects arrived after a light breakfast. Baseline hemodynamic parameters were recorded in a sitting position after the values had stabilized. 
Zeiss retinal vessel analyzer (RVA)
The RVA (Imedos, Jena, Germany) is a commercially available system which comprises a fundus camera (Zeiss FF 450, Jena, Germany), a video camera, a high resolution video recorder, a real time monitor and a personal computer with a vessel diameter analyzing software. The RVA allows for a precise determination of retinal vessel diameter with a time resolution of 25 readings/second (9) . The fundus was illuminated with light in the range of wavelengths between 567nm and 587nm. In this spectral range, the contrast between retinal vessels and the surrounding tissue is optimal. Retinal irradiance was approximately 220µW/cm 2 , which is about 50 times lower than the maximum level allowed for constant illumination of the retina at the wavelengths mentioned above. The system provides excellent reproducibility and sensitivity (13) . In the present study, major temporal arteries and veins were studied.
Measurements of retinal venous diameters were taken between 1 and 2 disc diameters from the margin of the optic disc. Red blood cell velocity was measured at the same locations as retinal vessel diameters by using bi-directional laser Doppler velocimetry.
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In the present study, we used a fundus camera-based system with a single mode laser 
Laser interferometry
Pulse synchronous pulsations of the eye fundus were assessed by laser interferometry. The method is described in detail by Schmetterer and colleagues (18) .
Briefly, the eye is illuminated by the beam of a single mode laser diode ( =783nm) along the optical axis. The laser power of not more than 100µW is much lower than the limit set by the American National Standards Institute. The light is reflected at both the front side of the cornea and the retina. The two re-emitted waves produce interference fringes from which the distance changes between cornea and retina during a cardiac cycle can be calculated. The maximum distance change between cornea and retina is called fundus pulsation amplitude (FPA) and estimates the pulsatile blood flow component in the choroid (16, 19) .
Measurement of intraocular pressure (IOP)
The IOP was measured with a Goldmann applanation tonometer.
Statistical analysis
For data description and statistical analysis hemodynamic parameters were expressed as percentage change from baseline ( %). Effects of histamine and cimetidine on hemodynamic parameters were assessed by a two-way ANOVA model for repeated measurements. Results are given as mean ±SD. Post-hoc analysis was performed using planned comparison. Shapiro-Wilks' W test was used to test for normal data distribution. Calculations were performed using the Statistica® software package (Statsoft, USA).
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Results

Dose finding study
As depicted in figure 1 , administration of cimetidine induced a dose dependent decrease in pulse rate (ANOVA, p=0.015). Other systemic and ocular hemodynamic parameters remained unaffected by administration of cimetidine (data not shown).
Main study
Baseline values of hemodynamic and ocular blood flow parameters were comparable between study days as summarized in Table 1 .
Systemic hemodynamics and IOP
As shown in Figure 2 , administration of cimetidine induced a significant decrease of pulse rate (ANOVA, p=0.021), which was not altered by co-administration of histamine.
Administration of histamine tended to decrease MAP when placebo was coadministered (-4 ± 9%), but this effect was not different on the cimetidine study day (ANOVA, p = 0.17). PPA was not altered by either histamine or cimetidine administration. IOP remained unchanged during the whole study period on both study days (data not shown). The effect of histamine on isolated vessels was mainly attributed to the activation of H 1 receptors, although activation of H 2 receptors appears to contribute to the histamine response as well (7). Neither H 1 nor H 2 antagonists completely abolished the vasodilator response to histamine, but combined treatment with both antagonists totally suppressed the relaxing effect of histamine (7) . In addition, the vasodilatory effect of histamine was dependent on the endothelium, indicating for a role of nitric oxide in the signaling cascade (7). This is in keeping with a previous report from our group showing that the effects of histamine in the ophthalmic artery and the choroid were diminished by systemic nitric oxide-synthase inhibition, supporting the concept that the vasodilator actions of histamine in the eye at least partially depend on nitric oxide (17) .
Our data indicate that in vivo H 2 receptors do only play a minor role in mitigating the hemodynamic effects of histamine, because neither the histamine-induced vasodilator effects in the larger retinal vessels nor the effects on choroidal blood flow parameters Effect of histamine and cimetidine on ocular blood flow
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were altered by cimetidine. Could these results be false negative? We can not entirely exclude that higher doses of cimetidine may affect blood flow in the eye. On the other hand cimetidine was administered in a hemodynamically active dose as evidenced from the well known effect of the drug to induce a decrease in pulse rate (11) .
This result is somewhat unexpected, because in other vascular beds H 2 receptors do contribute to histamine-induced vascular effects. It is already known for a long time that the action of histamine on vascular smooth muscle may vary depending on the tissue and species. Furthermore, histamine responses are known to be location and concentration dependent. Even a segmental vessel heterogeneity of the response to histamine has been described explaining differences between in vitro and in vivo studies (22, 23) . Table 1 : Baseline parameters of ocular and systemic hemodynamic measurements on the two study days. Baseline parameters were obtained during the 10 minutes before infusion.
The averaging period for haemodynamic measurements with laser Doppler flowmetry and laser Doppler velocimetry was 120 seconds. Results are presented as means ± SD (n=18).
* Retinal blood flow denotes blood flow through one specific vein and not total blood flow.
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